Thursday, July 28, 2022

Decades of Alzheimer’s research may have been fabricated

 https://www.wkbn.com/news/national-world/decades-of-alzheimers-research-may-have-been-fabricated/

Years of crucial research into Alzheimer’s disease may have been tainted by made-up scientific findings, a new whistleblower report says.

Vanderbilt University neurologist Matthew Schrag, in a bombshell interview with Science, laid out findings he made that showed over a decade of industrywide Alzheimer’s research may have been based on fabricated pieces of evidence involving a plaque protein found in the brain.

Shrag alerted his findings to the National Institute of Health and the Food and Drug Administration but also went public in the media with findings he believes will have a big impact on Alzheimer’s research, a branch of science that gets millions of dollars in funding every year.

“You can cheat to get a paper. You can cheat to get a degree. You can cheat to get a grant. You can’t cheat to cure a disease,” Shrag told Science. “Biology doesn’t care.”

6 comments:

  1. it has already been known for 10 years, that the beta amyloid hypothesis is false.

    ReplyDelete
  2. Nope it it is still being actively debated

    ReplyDelete
  3. https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-014-0135-5






    “Whenever a theory appears to you as the only
    possible one, take this as a sign that you have neither understood the
    theory nor the problem which it was intended to solve.”





    Karl Popper

    ReplyDelete
  4. what is being actively debated, is how to scrap reserch programmes on anti- amyloid drugs, and what alternative approaches should be taken.


    Every drug trial, and drug, which can clear the beat amyloids, has failed to change, stop or improve the disease progression.




    This has been known in inudstry for the past 10 years, but the level of investment - $10s of billions, has caused inertia and paralysis in the research fields.




    https://www.frontiersin.org/articles/10.3389/fnins.2018.00025/full?mod=article_inline



    Aducanumab is the latest "approved" drug, which has little or no benefit, and is now being walked back.

    ReplyDelete
  5. Typical
    you find a single view and present it as if everyone accepts it - the issue is still being debated

    ReplyDelete
  6. typical, you latch on to a single, outdated view, and think it is mainstream, when you have bene out ot touch with the research community who hold differently

    ReplyDelete

ANONYMOUS COMMENTS WILL NOT BE POSTED!
please use either your real name or a pseudonym.